Pag-aaral pangklinika para sa Lymphoma sa Colorado
16 pag-aaral para sa Lymphoma ang naghahanap ng mga kalahok sa mga site sa Colorado.
Mga Lungsod sa Colorado
Opisyal na teksto ng pag-aaral (English)
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Children's Hospital Colorado, Aurora
Nagre-recruitObservasyonal na pag-aaral
Edad 0 hanggang 38 · Lahat ng kasarian · Na-update Okt 1, 2026 · NCT06131801A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
- University Of Colorado, Aurora
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT07015242A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- Children's Hospital Colorado - Anschutz Medical Campus, Aurora
Nagre-recruitPhase 1/2
Hanggang edad 25 · Lahat ng kasarian · Na-update Set 25, 2026 · NCT04094610A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- Colorado Blood Institute, Denver
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 17, 2026 · NCT07221500Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
- University of Colorado, Aurora
- Colorado Blood Cancer Institute (Sarah Cannon), Denver
Nagre-recruitPhase 1
Edad 18 hanggang 100 · Lahat ng kasarian · Na-update Set 15, 2026 · NCT05798897CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- Children's Hospital Colorado, Aurora
Nagre-recruitPhase 1/2
12 Months – 21 Years · Lahat ng kasarian · Na-update Set 11, 2026 · NCT04870944Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
- Research Site, Denver
Nagre-recruitPhase 3
Edad 18 hanggang 18 · Lahat ng kasarian · Na-update Set 8, 2026 · NCT07509151Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Colorado Blood Cancer Institute, Denver
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT05826535Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Colorado Blood Cancer Institute, Denver
Nagre-recruitPhase 1/2
Edad 13 hanggang 90 · Lahat ng kasarian · Na-update Ago 6, 2026 · NCT06533579A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- University of Colorado, Aurora
- Colorado Blood Cancer Institute, Denver
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 4, 2026 · NCT07188558DALY II USA/ MB-CART2019.1 for DLBCL
- Colorado Blood Cancer Institute, Denver
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 13, 2026 · NCT04792489A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
- Call for Information (Investigational Site 0019), Aurora
Nagre-recruitPhase 1/2
6 Months – 17 Years · Lahat ng kasarian · Na-update Hul 6, 2026 · NCT02332668A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Colorado Blood Cancer Institute, Denver
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 2, 2026 · NCT05131022Survivors Uniting for Remote Guided Exercise
- Human Performance Clinical Research Lab, Fort Collins
Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 31, 2026 · NCT07290309A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- Sarah Cannon Research Institute at Colorado Blood Cancer Institute, Denver
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 20, 2026 · NCT04830137Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
- University of Colorado Anschutz Medical Campus, Aurora
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2025 · NCT04234048Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.